Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Bipolar I Disorder
← catalyst calendarSponsored by Rapport Therapeutics Inc. (industry) · RAPP — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
253actual
Sites
20
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-07-25 | actual | When the study began enrolling |
| Primary completion | 2026-08-05 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Oct 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2025-07-01 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Bipolar 1 Disorder
Interventions
- Drug: RAP-219
- Other: Placebo
Primary outcome
what the primary-completion date above is the date OFYoung Mania Rating Scale (YMRS)
measured Baseline to End of Treatment at Week 3
Permalink · RAPP's whole pipeline · Catalyst calendar · Every registered study · What changed